ALK and non-small cell lung carcinoma: AKT inhibition alone or in combination with LOR had a minimal effect on the PI3K/AKT and MAPK signalling pathways in the EML4-ALK-negative NSCLC cell line, A549 (Supplementary Fig. S14G).